BackAlbireo Pharma Overview

Albireo Pharma Long Term Debt

Track Albireo Pharma's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00
↓ 100.00% YoYΔ $-9.93M vs prior year quarter

Peer trimmed avg / median

Loading

Albireo Pharma Long Term Debt History

Loading

Albireo Pharma vs. peers: Long Term Debt Comparison

Loading

Albireo Pharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Albireo Pharma (ALBO) FAQ

Albireo Pharma (ALBO) currently reports a long-term debt of $0 as of September 2022. That compares with $9.9M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Albireo Pharma's long-term debt history and peer comparisons.

Albireo Pharma's long-term debt decreased from $9.9M to $0 — a 100.0% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Albireo Pharma reported $0 in long-term debt as of September 2022. That compares with $9.9M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Albireo Pharma, and consider following ALBO for alerts when major investors trade the stock.

Albireo Pharma is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALBO with unrelated industries.